Literature DB >> 11454804

Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype.

I Nakano1, Y Fukuda, Y Katano, H Toyoda, K Hayashi, T Hayakawa, T Kumada, S Nakano.   

Abstract

BACKGROUND: Genotype 1b of hepatitis C virus (HCV) comprises mainly three subtypes, each named for its geographic prevalence (worldwide, W; Japan, J; and not in Japan, NJ). AIM: To characterise the newly identified subtypes of genotype 1b and to review factors associated with response to interferon (IFN) for each subtype. PATIENTS: Chronic hepatitis patients (80 men and 41 women; mean age 48.5 years, range 20.7--69.3) with HCV genotype 1b (W type, n=41; J type, n=38) or genotype 2a (n=42) were treated according to the same IFN protocol. Forty four patients (36.4%) negative for serum HCV RNA six months after cessation of treatment were considered complete responders.
METHODS: Factors associated with complete response were investigated.
RESULTS: Genotype 2a patients had lower viral loads (odds ratio 0.11 (95% confidence intervals (CI) 0.049--0.256)) and a better IFN response (odds ratio 0.25 (95% CI 0.117--0.552)) than genotype 1b patients whereas W type and J type patients had similar viral loads and responses to IFN. IFN response in W type patients was associated with female sex (odds ratio 0.23 (95% CI 0.055--0.983)) and low viral load (odds ratio 84.00 (95% CI 14.04--502.6)) whereas response in J type patients was related to transfusion history (odds ratio 7.20 (95% CI 1.443--35.91)), low viral load (odds ratio 117.0 (95% CI 17.82--768.3)), and genetic mutation in the interferon sensitivity determining region of the virus (odds ratio 0.08 (95% CI 0.013--0.553)). Multivariate analysis found low viral load (odds ratio 64.19 (95% CI 14.66--281.06)) to be the only significant independent factor associated with IFN response.
CONCLUSIONS: Factors associated with IFN responsiveness in HCV infection differ with viral subtype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454804      PMCID: PMC1728417          DOI: 10.1136/gut.49.2.263

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.

Authors:  S Zeuzem; J H Lee; W K Roth
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  The origin of hepatitis C virus genotypes.

Authors:  D B Smith; S Pathirana; F Davidson; E Lawlor; J Power; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1997-02       Impact factor: 3.891

3.  Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group.

Authors:  F Dubois; J C Desenclos; N Mariotte; A Goudeau
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

4.  Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

Authors:  Y Shiratori; N Kato; O Yokosuka; F Imazeki; E Hashimoto; N Hayashi; A Nakamura; M Asada; H Kuroda; N Tanaka; Y Arakawa; M Omata
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

5.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

6.  The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses.

Authors:  M Kobayashi; E Tanaka; T Sodeyama; A Urushihara; A Matsumoto; K Kiyosawa
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

7.  Hepatitis C virus: epidemiology and genotypes in the north east of England.

Authors:  J P Watson; A M Brind; C E Chapman; C L Bates; F K Gould; S J Johnson; A D Burt; J Ferguson; P Simmonds; M F Bassendine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.

Authors:  T Poynard; V Leroy; M Cohard; T Thevenot; P Mathurin; P Opolon; J P Zarski
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

9.  Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group.

Authors:  N N Zein; J Rakela; E L Krawitt; K R Reddy; T Tominaga; D H Persing
Journal:  Ann Intern Med       Date:  1996-10-15       Impact factor: 25.391

10.  Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.

Authors:  H Khorsi; S Castelain; A Wyseur; J Izopet; V Canva; A Rombout; D Capron; J P Capron; F Lunel; L Stuyver; G Duverlie
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.